Logo image
Back
Advances in HPV Vaccination in People Living with HIV: A Review
Journal article   Open access   Peer reviewed

Advances in HPV Vaccination in People Living with HIV: A Review

Megan Mooberry, J. Brooks Jackson and Mary B. Rysavy
Vaccines (Basel), Vol.14(2), 194
02/21/2026
DOI: 10.3390/vaccines14020194
PMCID: PMC12944972
PMID: 41746114
url
https://doi.org/10.3390/vaccines14020194View
Published (Version of record) Open Access

Abstract

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide and is a leading cause of cervical, anal, penile, and oropharyngeal cancers. This review summarizes the epidemiology of HPV and the immunogenicity, clinical efficacy, and current HPV vaccination recommendations among people living with HIV (PLWH). PLWH experience a disproportionate burden of HPV-related infection and HPV-related malignancies. Although HPV vaccines have been shown to be highly effective, vaccination coverage among PLWH remains suboptimal, particularly in low- and middle-income countries. Barriers to vaccination include extended dosing schedules, limited awareness of the vaccine, and misinformation. Evidence indicates HPV vaccines are safe and induce a robust antibody response in PLWH, especially among individuals with higher CD4+ cell counts and viral suppression on antiretroviral therapy. However, evidence for reduction in clinical HPV-related disease in this population remains limited. Ongoing research is aimed at optimizing the HPV vaccination schedule for PLWH and expanding vaccination in older, high-risk subgroups. Integrating HPV vaccination into HIV care is essential to reduce HPV-related morbidity and mortality in PLWH.
 Review

Details

Metrics

4 Record Views
Logo image